Emergent Biosolutions Shares Outstanding 2010-2022 | EBS

Emergent Biosolutions shares outstanding from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Emergent Biosolutions Annual Shares Outstanding
(Millions of Shares)
2021 54
2020 54
2019 52
2018 51
2017 50
2016 49
2015 47
2014 46
2013 37
2012 36
2011 36
2010 33
2009 31
Emergent Biosolutions Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 50
2022-03-31 51
2021-12-31 54
2021-09-30 54
2021-06-30 54
2021-03-31 55
2020-12-31 54
2020-09-30 54
2020-06-30 54
2020-03-31 52
2019-12-31 52
2019-09-30 52
2019-06-30 52
2019-03-31 51
2018-12-31 51
2018-09-30 52
2018-06-30 51
2018-03-31 50
2017-12-31 50
2017-09-30 50
2017-06-30 50
2017-03-31 50
2016-12-31 49
2016-09-30 49
2016-06-30 40
2016-03-31 48
2015-12-31 47
2015-09-30 48
2015-06-30 47
2015-03-31 38
2014-12-31 46
2014-09-30 47
2014-06-30 38
2014-03-31 37
2013-12-31 37
2013-09-30 37
2013-06-30 37
2013-03-31 36
2012-12-31 36
2012-09-30 37
2012-06-30 37
2012-03-31 36
2011-12-31 36
2011-09-30 36
2011-06-30 37
2011-03-31 35
2010-12-31 33
2010-09-30 32
2010-06-30 32
2010-03-31 31
2009-12-31 31
2009-09-30 32
2009-06-30 31
2009-03-31 31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.465B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.286B 9.60
GSK (GSK) United Kingdom $71.707B 8.61
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.077B 18.55
Biohaven Pharmaceutical Holding (BHVN) United States $10.582B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.645B 0.00
Arcus Biosciences (RCUS) United States $1.982B 38.68
Myovant Sciences (MYOV) United Kingdom $1.693B 0.00
Zymeworks (ZYME) Canada $0.405B 0.00
Enzo Biochem (ENZ) United States $0.132B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
Ambrx Biopharma (AMAM) United States $0.099B 0.00
SQZ Biotechnologies (SQZ) United States $0.096B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00